Asset profile
AD-214
Antibody-derived scaffold
Evidence outlook · program status
On hold, as a strategic decision by the sponsor
AD-214 is AdAlta's anti-CXCR4 i-body Fc-fusion protein for fibrotic disease, whose Phase 1 study included chronic kidney disease patients. AdAlta has pivoted to an in-licensed 'East to West' CAR-T pipeline, and its own website now describes AD-214 in the past tense and says the company is seeking external partners to fund a Phase 2, so in-house development is paused rather than terminated. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 0 direct rivals (same mechanism and indication), 4 same-class, 60 same-indication; 64 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AD-214: this drug | Phase 1 | Antibody-derived scaffold | CXCR4 | ||
| Motixafortide | Approved | Peptide | CXCR4 | ||
| Plerixafor | Approved | Small molecule | CXCR4 | ||
| Burixafor (TG-0054) | Phase 2 | Small molecule | CXCR4 | ||
| GPC-100 | Phase 2 | Small molecule | CXCR4 | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Daprodustat (Jesduvroq) | Approved | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Difelikefalin (Korsuva) | Approved | Peptide | Kappa-opioid receptor (agonist, peripherally restricted) | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Etelcalcetide (Parsabiv) | Approved | Peptide | Calcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cells | ||
| Extended-Release Calcifediol (Rayaldee) | Approved | Small molecule | Vitamin D receptor (VDR), via conversion to calcitriol |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.